OptiNose, Inc. (OPTN)
NASDAQ: OPTN · Real-Time Price · USD
9.17
+0.02 (0.22%)
Mar 31, 2025, 4:00 PM EDT - Market closed
Company Description
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States.
The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.
It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail.
The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.
OptiNose, Inc.
| Country | United States |
| Founded | 2010 |
| IPO Date | Oct 13, 2017 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 132 |
| CEO | Ramy Mahmoud |
Contact Details
Address: 1020 Stony Hill Road, Suite 300 Yardley, Pennsylvania 19067 United States | |
| Phone | 267 364 3500 |
| Website | optinose.com |
Stock Details
| Ticker Symbol | OPTN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001494650 |
| CUSIP Number | 68404V100 |
| ISIN Number | US68404V1008 |
| Employer ID | 42-1771610 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ramy A. Mahmoud M.D., M.P.H. | Chief Executive Officer and Director |
| Michael F. Marino Esq. | Chief Legal Officer and Corporate Secretary |
| Paul Spence | Chief Commercial Officer |
| P. Terence Kohler | Chief Financial Officer |
| Anthony J. Krick | Vice President of Finance and Chief Accounting Officer |
| Jonathan Neely | Vice President of Investor Relations and Business Development |
| Karen E. Brophy | Chief Human Resources Officer and Vice President of Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 26, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 26, 2025 | 10-K | Annual Report |
| Mar 26, 2025 | 8-K | Current Report |
| Mar 21, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 20, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 20, 2025 | 8-K | Current Report |
| Mar 20, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 20, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 20, 2025 | 8-K | Current Report |
| Mar 14, 2025 | 144 | Filing |